Literature DB >> 17308157

Fetal growth restriction and postnatal development.

Makarios Eleftheriades1, George Creatsas, Kypros Nicolaides.   

Abstract

The interaction between genetic constitution and in utero environment determines fetal growth and development and influences the susceptibility to certain disorders in adulthood. Data from both animal and human studies indicate that prenatal and early postnatal malnutrition can program the hypothalamus-pituitary-adrenal axis (HPA axis), altering neuroendocrine response to stressors throughout lifetime. Impaired uteroplacental perfusion results in fetal growth restriction (FGR). In FGR there is evidence of chronic hypoxemia and alterations in metabolic, endocrine, and hematological parameters, compatible with starvation. Furthermore, FGR is associated with increased perinatal mortality and in the survivors there is increased susceptibility to diabetes and cardiovascular disease in adulthood. There is evidence that early postnatal growth acceleration, which would normally be considered desirable, may exacerbate metabolic dysfunction in later life.

Entities:  

Mesh:

Year:  2006        PMID: 17308157     DOI: 10.1196/annals.1365.047

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  17 in total

Review 1.  Maternal micronutrient restriction programs the body adiposity, adipocyte function and lipid metabolism in offspring: a review.

Authors:  K Rajender Rao; I J N Padmavathi; M Raghunath
Journal:  Rev Endocr Metab Disord       Date:  2012-06       Impact factor: 6.514

2.  Assessment of body composition in Wistar rat offspring by DXA in relation to prenatal and postnatal nutritional manipulation.

Authors:  Makarios Eleftheriades; Homeira Vafaei; Ismene Dontas; George Vaggos; Katerina Marinou; Panagiota Pervanidou; Neil J Sebire; George P Chrousos; Kypros H Nicolaides
Journal:  Pediatr Res       Date:  2016-04-08       Impact factor: 3.756

3.  Organ-specific defects in insulin-like growth factor and insulin receptor signaling in late gestational asymmetric intrauterine growth restriction in Cited1 mutant mice.

Authors:  Tatiana Novitskaya; Mariana Baserga; Mark P de Caestecker
Journal:  Endocrinology       Date:  2011-04-12       Impact factor: 4.736

4.  Antenatal taurine improves neuronal regeneration in fetal rats with intrauterine growth restriction by inhibiting the Rho-ROCK signal pathway.

Authors:  Jing Liu; Hua-Wei Wang; Fang Liu; Xiao-Feng Wang
Journal:  Metab Brain Dis       Date:  2014-05-28       Impact factor: 3.584

Review 5.  The Transitional Heart: From Early Embryonic and Fetal Development to Neonatal Life.

Authors:  Cheryl Mei Jun Tan; Adam James Lewandowski
Journal:  Fetal Diagn Ther       Date:  2019-09-18       Impact factor: 2.587

6.  Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.

Authors:  Ian Damerill; Kyle K Biggar; Majida Abu Shehab; Shawn Shun-Cheng Li; Thomas Jansson; Madhulika B Gupta
Journal:  Mol Endocrinol       Date:  2015-12-29

Review 7.  Role of hypoxia during nephrogenesis.

Authors:  Shelby L Hemker; Sunder Sims-Lucas; Jacqueline Ho
Journal:  Pediatr Nephrol       Date:  2016-02-12       Impact factor: 3.714

8.  Placental insufficiency associated with loss of Cited1 causes renal medullary dysplasia.

Authors:  Duncan B Sparrow; Scott C Boyle; Rebecca S Sams; Bogdan Mazuruk; Li Zhang; Gilbert W Moeckel; Sally L Dunwoodie; Mark P de Caestecker
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

9.  Length of prenatal participation in WIC and risk of delivering a small for gestational age infant: Florida, 1996-2004.

Authors:  Ralitza Gueorguieva; Steven B Morse; Jeffrey Roth
Journal:  Matern Child Health J       Date:  2008-07-26

10.  Interinstitutional variation in prediction of death by SNAP-II and SNAPPE-II among extremely preterm infants.

Authors:  Olaf Dammann; Bhavesh Shah; Mary Naples; Francis Bednarek; John Zupancic; Elizabeth N Allred; Alan Leviton
Journal:  Pediatrics       Date:  2009-10-26       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.